Bosutinib-induced lung injury: a report of two cases and literature review.
Bosutinib
Chronic myeloid leukemia
Drug-induced lung injury
Steroid pulse treatment
Tyrosine kinase inhibitor
Journal
International journal of hematology
ISSN: 1865-3774
Titre abrégé: Int J Hematol
Pays: Japan
ID NLM: 9111627
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
received:
02
12
2021
accepted:
31
01
2022
revised:
31
01
2022
pubmed:
2
3
2022
medline:
7
6
2022
entrez:
1
3
2022
Statut:
ppublish
Résumé
The prognosis of patients with chronic myeloid leukemia (CML) has improved dramatically since the development of tyrosine kinase inhibitors (TKIs). Three second-generation TKIs, including bosutinib, are currently approved for treatment of CML, and show a faster and deeper clinical response than imatinib. Common adverse events (AEs) of bosutinib are diarrhea and hepatic toxicity; however, lung complications are rare. Here, we report two cases of bosutinib-induced severe lung injury, along with a literature review. The events of these cases occurred at early time points and severity was extremely high, requiring high-flow oxygen and steroid treatments. Compared to previously reported cases, the prevalence and severity of the damage may vary among different ethnicities. However, bosutinib-induced lung injury can cause life-threatening complications. In conclusion, patients treated with bosutinib should be monitored carefully to mitigate serious drug-induced lung injury.
Identifiants
pubmed: 35229254
doi: 10.1007/s12185-022-03304-0
pii: 10.1007/s12185-022-03304-0
pmc: PMC8884415
doi:
Substances chimiques
Aniline Compounds
0
Antineoplastic Agents
0
Nitriles
0
Protein Kinase Inhibitors
0
Quinolines
0
bosutinib
5018V4AEZ0
Types de publication
Case Reports
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
902-905Informations de copyright
© 2022. Japanese Society of Hematology.
Références
Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34:966–84.
doi: 10.1038/s41375-020-0776-2
Cortes JE, Gambacorti-Passerini C, Deininger MW, Mauro MJ, Chuah C, Kim DW, et al. Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial. J Clin Oncol. 2018;36:231–7.
doi: 10.1200/JCO.2017.74.7162
Moguillansky NI, Fakih HAM, Wingard JR. Bosutinib induced pleural effusions: case report and review of tyrosine kinase inhibitors induced pulmonary toxicity. Respir Med Case Rep. 2017;21:154–7.
pubmed: 28560147
pmcid: 5435591
Gambacorti-Passerini C, Kantarjian HM, Kim DW, Khoury HJ, Turkina AG, Brummendorf TH, et al. Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors. Am J Hematol. 2015;90:755–68.
doi: 10.1002/ajh.24034
Jutant EM, Meignin V, Montani D, Tazi A, Rousselot P, Bergeron A. Bosutinib-related pneumonitis. Eur Respir J. 2017;50:1700930.
doi: 10.1183/13993003.00930-2017
Liu QS, Ass’ad NA, Arana YC. Bosutinib-associated interstitial lung disease and pleural effusion: a case report and literature review. Clin Case Rep. 2021;9:e03164.
pubmed: 34094551
Ohnishi H, Yokoyama A, Yasuhara Y, Watanabe A, Naka T, Hamada H, et al. Circulating KL-6 levels in patients with drug induced pneumonitis. Thorax. 2003;58:872–5.
doi: 10.1136/thorax.58.10.872
Schwaiblmair M, Behr W, Haeckel T, Markl B, Foerg W, Berghaus T. Drug induced interstitial lung disease. Open Respir Med J. 2012;6:63–74.
doi: 10.2174/1874306401206010063
Danson S, Blackhall F, Hulse P, Ranson M. Interstitial lung disease in lung cancer: separating disease progression from treatment effects. Drug Saf. 2005;28:103–13.
doi: 10.2165/00002018-200528020-00002
Kamata Y, Nara H, Kamimura T, Haneda K, Iwamoto M, Masuyama J, et al. Rheumatoid arthritis complicated with acute interstitial pneumonia induced by leflunomide as an adverse reaction. Intern Med. 2004;43:1201–4.
doi: 10.2169/internalmedicine.43.1201
Miyakoshi S, Kami M, Yuji K, Matsumura T, Takatoku M, Sasaki M, et al. Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma. Blood. 2006;107:3492–4.
doi: 10.1182/blood-2005-11-4541
Cortes JE, Apperley JF, DeAngelo DJ, Deininger MW, Kota VK, Rousselot P, et al. Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review. J Hematol Oncol. 2018;11:143.
doi: 10.1186/s13045-018-0685-2
Steegmann JL, Baccarani M, Breccia M, Casado LF, Garcia-Gutierrez V, Hochhaus A, et al. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia. 2016;30:1648–71.
doi: 10.1038/leu.2016.104
Guignabert C, Phan C, Seferian A, Huertas A, Tu L, Thuillet R, et al. Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension. J Clin Invest. 2016;126:3207–18.
doi: 10.1172/JCI86249
Noguchi T, Sekiguchi Y, Kudoh Y, Naganuma R, Kagi T, Nishidate A, et al. Gefitinib initiates sterile inflammation by promoting IL-1beta and HMGB1 release via two distinct mechanisms. Cell Death Dis. 2021;12:49.
doi: 10.1038/s41419-020-03335-7